A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity.
暂无分享,去创建一个
O. Nishimura | M. Baba | M. Fujino | H. Sawada | M. Okamoto | M Baba | N. Kanzaki | M Fujino | O Nishimura | N Kanzaki | M Okamoto | H Sawada | Y Iizawa | M Shiraishi | Y Aramaki | K Okonogi | Y Ogawa | K Meguro | M. Shiraishi | Y. Iizawa | K. Meguro | Y. Aramaki | K. Okonogi | Y. Ogawa | Y. Ogawa | H. Sawada | Osamu Nishimura | Kanji Meguro
[1] J. Albert,et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.
[2] J Desmyter,et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. , 1988, Journal of virological methods.
[3] P. Gray,et al. Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine Receptor (CCR5) for RANTES, MIP-1β, and MIP-1α* , 1996, The Journal of Biological Chemistry.
[4] J. Sodroski,et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia , 1997, Nature.
[5] Stephen C. Peiper,et al. Identification of a major co-receptor for primary isolates of HIV-1 , 1996, Nature.
[6] J. Moore,et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor , 1998, Nature Medicine.
[7] Marc Parmentier,et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.
[8] J. Hoxie,et al. Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. , 1998, Journal of immunology.
[9] B. Hyman,et al. Role of the β-Chemokine Receptors CCR3 and CCR5 in Human Immunodeficiency Virus Type 1 Infection of Monocytes and Microglia , 1998, Journal of Virology.
[10] E. De Clercq,et al. T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor 1α Contains Mutations in the Envelope gp120 but Does Not Show a Switch in Coreceptor Use , 1998, Journal of Virology.
[11] D. Richman,et al. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.
[12] Marc Parmentier,et al. A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion Cofactors , 1996, Cell.
[13] M. Emerman,et al. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene , 1992, Journal of virology.
[14] T. Schwartz,et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.
[15] E. De Clercq,et al. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[16] G Vassart,et al. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. , 1996, Biochemistry.
[17] P. Luciw,et al. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection , 1997, Journal of virology.
[18] R. Connor,et al. Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.
[19] Douglas Richman,et al. Viral Dynamics of HIV: Implications for Drug Development and Therapeutic Strategies , 1996, Annals of Internal Medicine.
[20] E. Fenyö,et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression , 1997, Nature Medicine.
[21] Ying Sun,et al. The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates , 1996, Cell.
[22] E. Clercq,et al. Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.
[23] Virginia Litwin,et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 , 1996, Nature.
[24] H. Schuitemaker,et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.
[25] C. Mackay,et al. Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding , 1997, The Journal of experimental medicine.
[26] A. Luster,et al. Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.
[27] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[28] C. Broder,et al. CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.
[29] M. Montjovent,et al. Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist (*) , 1996, The Journal of Biological Chemistry.
[30] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.
[31] Richard A Koup,et al. Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.
[32] M. Mack,et al. Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.
[33] S. Arya,et al. Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.